Table 1 Characteristics of the study population.
From: Prediction of early-stage melanoma recurrence using clinical and histopathologic features
Characteristic | Non-recurrence (N = 1410) | Recurrence (N = 310) | p-value |
|---|---|---|---|
Institution | |||
DFCI | 453 (32.1%) | 95 (30.6%) | 0.660 |
MGB | 957 (67.9%) | 215 (69.4%) | |
Duration of follow-up (year) | |||
Median [IQR] | 7.3 [3.8, 12.2] | 5.8 [3.2, 9.3] | <0.001 |
Recurrence type | |||
Distant | Not applicable | 151 (48.7%) | |
Locoregional | Not applicable | 159 (51.3%) | |
Time to recurrence (year) | |||
Median [IQR] | Not applicable | 1.9 [0.9, 3.9] | |
Time to locoregional recurrence (year) | |||
Median [IQR] | Not applicable | 1.5 [0.9, 3.1] | |
Time to distant recurrence (year) | |||
Median [IQR] | Not applicable | 2.5 [1.3, 4.5] | |
Mortality status | |||
Alive | 1106 (78.4%) | 158 (51.0%) | <0.001 |
Dead | 304 (21.6%) | 152 (49.0%) | |
Year of diagnosis | |||
2000–2005 | 364 (25.8%) | 59 (19.0%) | 0.020 |
2006–2010 | 388 (27.5%) | 88 (28.4%) | |
2011–2015 | 514 (36.5%) | 117 (37.7%) | |
2016–2020 | 144 (10.2%) | 46 (14.8%) | |
Age at diagnosis (year) | |||
Median [IQR] | 60 [47, 70] | 65 [55, 76] | <0.001 |
Sex | |||
Female | 638 (45.2%) | 112 (36.1%) | 0.004 |
Male | 772 (54.8%) | 198 (63.9%) | |
Race | |||
White | 1399 (99.2%) | 304 (98.1%) | 0.122 |
Unavailable/Other | 11 (0.8%) | 6 (1.9%) | |
Histology type | |||
Lentigo maligna melanoma | 107 (7.6%) | 23 (7.4%) | <0.001 |
Melanoma, NOS | 269 (19.1%) | 67 (21.6%) | |
Nodular melanoma | 115 (8.2%) | 85 (27.4%) | |
Superficial spreading melanoma | 919 (65.2%) | 135 (43.5%) | |
Site | |||
Skin of face | 147 (10.4%) | 51 (16.5%) | <0.001 |
Skin of lower limb and hip | 268 (19.0%) | 65 (21.0%) | |
Skin of scalp and neck | 84 (6.0%) | 46 (14.8%) | |
Skin of trunk | 542 (38.4%) | 89 (28.7%) | |
Skin of upper limb and shoulder | 369 (26.2%) | 59 (19.0%) | |
AJCC Stage | |||
1A | 862 (61.1%) | 49 (15.8%) | <0.001 |
1B | 386 (27.4%) | 84 (27.1%) | |
2A | 71 (5.0%) | 58 (18.7%) | |
2B | 62 (4.4%) | 63 (20.3%) | |
2C | 29 (2.1%) | 56 (18.1%) | |
Breslow thickness | |||
Mean (SD) | 1.0 (1.4) | 3.0 (4.2) | <0.001 |
Median [IQR] | 0.6 [0.04, 1.1] | 2.0 [1.1, 3.9] | |
Anatomic level | |||
Mean (SD) | 3.2 (0.9) | 4.0 (0.8) | <0.001 |
Median [IQR] | 3.0 [2.0, 4.0] | 4.0 [4.00, 4.0] | |
Ulceration | |||
Absent | 1305 (92.6%) | 210 (67.7%) | <0.001 |
Present | 101 (7.2%) | 99 (31.9%) | |
Unavailable | 4 (0.3%) | 1 (0.3%) | |
Mitotic rate (mitoses/mm2) | |||
Mean (SD) | 1.8 (3.5) | 7.6 (11.0) | <0.001 |
Median [IQR] | 1.0 [0.0, 2.0] | 4.0 [2.0, 10.0] | |
Regional lymph node histology | |||
Not indicated | 826 (58.6%) | 55 (17.7%) | <0.001 |
All nodes negative | 519 (36.8%) | 175 (56.5%) | |
Not performed: unknown reason | 30 (2.1%) | 12 (3.9%) | |
Not performed: due to age/comorbidity | 30 (2.1%) | 59 (19.0%) | |
Not performed: deferred by patient | 5 (0.4%) | 9 (2.9%) |
